Date: 2014-03-10
Type of information: Milestone
Compound: drug discovery services for novel anti-bacterial agents
Company: Antabio (France) Argenta (Galapagos subsidiary – UK Belgium)
Therapeutic area: Infectious diseases
Type agreement: R&D
collaboration
Action mechanism:
Disease:
Details: * On February 7, 2013, Argenta, a Galapagos company that provides drug discovery services from target validation to proof of concept, and Antabio have signed a collaboration agreement. Under the terms of the agreement, Argenta will provide medicinal chemistry, computer-aided drug design and ADME/PK services, together with its integrated drug discovery expertise, to assist Antabio in the identification of novel anti-bacterial agents and discovery of a development candidate that can be progressed into clinical trials. The collaboration is funded by a Wellcome Trust Seeding Drug Discovery award. Antabio’s first-in-class, small molecule compounds offer a synergistic solution to the shortfall of current antibacterial agents.The company is developing new drugs that will work with existing antibiotics to enable them to regain their activity against multi- or pan-drug resistant Gram-negative pathogens such as NDM-1 bacteria.
Financial terms:
Latest news: * On March 10, 2014, Argenta, a Galapagos company that provides drug discovery services from target validation to proof of concept, has announced that it has achieved a milestone with its collaboration partner Antabio in an anti-bacterial drug discovery project funded by the Wellcome Trust. The attainment of the milestone triggers the drawdown of a further €1.7 million tranche of their Seeding Drug Discovery Award. A novel lead series of pan-metallo beta-lactamase inhibitors has been identified that, in combination with carbapenems, restores antibacterial activity against life-threatening clinical isolates whilst exhibiting no toxicity or developmental issues.
The Argenta/Antabio collaboration began in February 2013, when the Wellcome Trust awarded Antabio €4.7 Million to fund the discovery of a novel, safe and efficacious pan-inhibitor of bacterial metallo beta-lactamases (MBLs). Since then, Argenta has provided medicinal chemistry, computer-aided drug design and ADME/PK services, together with its integrated drug discovery expertise, to assist Antabio achieve its research goals.
